Guangzhou Innogen Pharmaceutical Group (HKG:2591) raised HK$634.7 million in net proceeds from its initial public offering in Hong Kong, according to a Thursday after-market Hong Kong bourse filing.
The pharmaceutical firm priced its 36,556,400 H-shares at HK$18.68 apiece.
The Hong Kong public offer was 5,341.66 times oversubscribed, with the final allocation of 3,655,800 shares, or about 10% of the total offering, unchanged from the initial allotment.
The international offering was 10.67 times subscribed, with the final number of shares offered remaining at 32,900,600.
Cornerstone investors June Star Global, Ginkgo Capital Global Fund - SPC XtalPi AI Fund SP, Marketingforce Management, Deng Haifeng, and Li Huifeng were allotted a combined 4,201,000 shares, or about 11.49% of the global offering.
Guangzhou Innogen Pharma is set to debut on the Hong Kong bourse on Friday, Aug. 15.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。